The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance
Open accessAbstract
Isoniazid (INH), a frontline antitubercular drug, inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis , by forming a covalent adduct with the NAD cofactor. Here, we report that the INH-NAD adduct is a slow, tight-binding competitive inhibitor of InhA. Demonstration that the adduct binds to WT InhA by a two-step enzyme inhibition mechanism, with initial, weak binding ( K –1 = 16 ± 11 nM) followed by slow conversion to a final inhibited complex (EI*) with overall K i = 0.75 ± 0.08 nM, reconciles existing contradictory values for the inhibitory potency of INH-NAD for InhA. The first order rate constant for conversion of the initial EI complex to EI* ( k 2 = 0.13 ± 0.01 min –1 ) is similar to the maximum rate constant observed for InhA inhibition in reaction mixtures containing InhA, INH, NADH, and the INH-activating enzyme KatG (catalase/peroxidase from M. tuberculosis ), consistent with an inhibition mechanism in which the adduct forms in solution rather than on the enzyme. Importantly, three mutations that correlate with INH resistance, I21V, I47T, and S94A, have little impact on the inhibition constants. Thus, drug resistance does not result simply from a reduction in affinity of INH-NAD for pure InhA. Instead, we hypothesize that protein–protein interactions within the FASII complex are critical to the mechanism of INH action. Finally, for M161V, an InhA mutation that correlates with resistance to the common biocide triclosan in Mycobacterium smegmatis , binding to form the initial EI complex is significantly weakened, explaining why this mutant inactivates more slowly than WT InhA when incubated with INH, NADH, and KatG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Tuberculosis: Commentary on a Reemergent Killer
Bloom, B. R., & Murray, C. J. L. (1992) · Science · doi:10.1126/science.257.5073.1055 · Cited by 1,373
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Triclosan targets lipid synthesis
McMurry, L. M., Oethinger, M., & Levy, S. B. (1998) · Nature · doi:10.1038/28970 · Cited by 1,019
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis
Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R., & Sacchettini, J. C. (1998) · Science · doi:10.1126/science.279.5347.98 · Cited by 682
Antimicrobial agent resistance in mycobacteria: molecular genetic insights
Musser, J. M. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.496 · Cited by 621
Wilson, M., DeRisi, J., Kristensen, H.-H., Imboden, P., Rane, S., Brown, P. O., & Schoolnik, G. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12833 · Cited by 547
Crystal Structure and Function of the Isoniazid Target of Mycobacterium tuberculosis
Dessen, A., Quémard, A., Blanchard, J. S., Jacobs, W. R., & Sacchettini, J. C. (1995) · Science · doi:10.1126/science.7886450 · Cited by 430
Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP Synthase by Isoniazid
Mdluli, K., Slayden, R. A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D. D., Musser, J. M., & Barry, C. E. (1998) · Science · doi:10.1126/science.280.5369.1607 · Cited by 398
Enzymic Characterization of the Target for Isoniazid in Mycobacterium tuberculosis
Quemard, A., Sacchettini, J. C., Dessen, A., Vilcheze, C., Bittman, R., Jacobs, W. R., & Blanchard, J. S. (1995) · Biochemistry · doi:10.1021/bi00026a004 · Cited by 373
Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives
Rattan, A., Kalia, A., & Ahmad, N. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0402.980207 · Cited by 355
Ramaswamy, S. V., Reich, R., Dou, S.-J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T., & Graviss, E. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1241-1250.2003 · Cited by 336
Musser, J. M., Kapur, V., Williams, D. L., Kreiswirth, B. N., van Soolingen, D., & van Embden, J. D. A. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.196 · Cited by 313
Rozwarski, D. A., Vilchèze, C., Sugantino, M., Bittman, R., & Sacchettini, J. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15582 · Cited by 290
Vilchèze, C., Morbidoni, H. R., Weisbrod, T. R., Iwamoto, H., Kuo, M., Sacchettini, J. C., & Jacobs, W. R. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.14.4059-4067.2000 · Cited by 283
Johnsson, K., & Schultz, P. G. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00095a063 · Cited by 278
Heym, B., Honoré, N., Schurra, C., Cole, S. T., Heym, B., Truffot-Pernot, C., Grosset, J. H., Banerjee, A., Jacobs, W. R., & van Embden, J. D. A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91338-2 · Cited by 263
Inhibition of InhA, the Enoyl Reductase from Mycobacterium tuberculosis, by Triclosan and Isoniazid
Parikh, S. L., Xiao, G., & Tonge, P. J. (2000) · Biochemistry · doi:10.1021/bi0008940 · Cited by 238
Self-citationMarrakchi, H., Lanéelle, G., & Quémard, A. (2000) · Microbiology · doi:10.1099/00221287-146-2-289 · Cited by 238
Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis
Johnsson, K., King, D. S., & Schultz, P. G. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00122a038 · Cited by 215
Genetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan
McMurry, L. M., McDermott, P. F., & Levy, S. B. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.711 · Cited by 214
Action Mechanism of Antitubercular Isoniazid
Lei, B., Wei, C.-J., & Tu, S.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2520 · Cited by 208
Larsen, M. H., Vilchèze, C., Kremer, L., Besra, G. S., Parsons, L., Salfinger, M., Heifets, L., Hazbon, M. H., Alland, D., Sacchettini, J. C., et al. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03162.x · Cited by 202
Marrakchi, H., Ducasse-Cabanot, S., Labesse, G., Montrozier, H. L., Margeat, E., Emorine, L. J., Charpentier, X., Daffé, M., & Quémard, A. (2002) · Microbiology · doi:10.1099/00221287-148-4-951 · Cited by 158
Slayden, R. A., Lee, R. E., Jr., & Barry, C. E. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.02145.x · Cited by 153
Parikh, S. L., Moynihan, D. P., Xiao, G., & Tonge, P. J. (1999) · Biochemistry · doi:10.1021/bi990529c · Cited by 147
Self-citationBasso, L. A., Zheng, R., Musser, J. M., Jacobs, W. R., & Blanchard, J. S. (1998) · The Journal of Infectious Diseases · doi:10.1086/515362 · Cited by 133
Heinz, U., Hegetschweiler, Κ., Acklin, P., Faller, B., Lattmann, R., & Schnebli, H. P. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990903)38:17<2588::aid-anie2588>3.0.co;2-8 · Cited by 131
Hood, D. B., Huntington, J. A., & Gettins, P. G. W. (1994) · Biochemistry · doi:10.1021/bi00194a020 · Cited by 98
Quémard, A., Dessen, A., Sugantino, M., Jacobs, W. R., Sacchettini, J. C., & Blanchard, J. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja950998b · Cited by 90
Nguyen, M., Quémard, A., Broussy, S., Bernadou, J., & Meunier, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2137-2144.2002 · Cited by 86
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas
Bébéar, C. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.5.711 · Cited by 82
Kremer, L., Dover, L. G., Morbidoni, H. R., Vilchèze, C., Maughan, W. N., Baulard, A. R., Tu, S., Honoré, N., Deretic, V. P., Sacchettini, J. C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302435200 · Cited by 81
High-performance ion-exchange separation of oxidized and reduced nicotinamide adenine dinucleotides
Orr, G. A., & Blanchard, J. S. (1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90544-x · Cited by 71
Stoeckle, M. Y., Guan, L. L., Riegler, N., Weitzman, I., Kreiswirth, B. N., Kornblum, J. S., Laraque, F., & Riley, L. W. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.4.1063 · Cited by 70
Basso, L. A., Zheng, R., & Blanchard, J. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962035y · Cited by 39
Cited by
THE STRUCTURAL BIOLOGY OF TYPE II FATTY ACID BIOSYNTHESIS
White, S. W., Zheng, J., Zhang, Y.-M., & Rock, C. O. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133524 · Cited by 832
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY
Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., & Williams, D. P. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100058 · Cited by 453
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Metadata
- Authors
- Rawat, R., Whitty, A., & Tonge, P. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-11-17
- Volume
- 100
- Issue
- 24
- Pages
- 13881-13886
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2036391785
- Cited by
- 330
- References
- 37
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.